Avisi Technologies is a clinical-stage ophthalmic medical device company building VisiPlate, an ultrathin, nanotechnology-enabled aqueous shunt that drains excess fluid from the eye to lower pressure in glaucoma patients. Spun out of the University of Pennsylvania's Y-Prize program in 2017, the company is advancing VisiPlate through the FDA-cleared SAPPHIRE pivotal trial and has raised roughly $21.7M to date, including a $10.7M Series A in February 2026.
QURA, Inc. is a preclinical medical-technology company in Massachusetts building a tiny implanted sensor that continuously measures blood pressure and wirelessly transmits medical-grade waveform data to patients and physicians in real time. Its QSmart platform - a vitamin-sized QSense implant paired with software and analytics - aims to replace the occasional cuff reading with always-on monitoring, targeting hypertension, the leading cardiovascular risk factor worldwide. The technology grew out of an earlier wireless implantable pressure sensor developed for glaucoma (intraocular pressure) monitoring.
ViaLase, Inc. is a clinical-stage medical technology company in Aliso Viejo, California building the first femtosecond laser designed to treat primary open-angle glaucoma without cutting into the eye. Its ViaLuxe Laser System pairs micron-level, high-definition imaging with a femtosecond laser to perform a noninvasive, image-guided trabeculotomy - branded FLigHT - that creates a drainage channel through the trabecular meshwork to lower intraocular pressure. Founded in 2019 by femtosecond-laser pioneer Tibor Juhasz, the company has raised more than $115 million, earned a CE Mark in Europe, and begun a U.S. IDE clinical trial.
Rui Jing Jiang is the Founder and CEO of Avisi Technologies, a Redwood City-based clinical-stage medical device company developing VisiPlate, the world's thinnest freestanding ophthalmic implant for treating glaucoma. Built on University of Pennsylvania nanotechnology, VisiPlate is a multichannel aqueous shunt composed of alumina and Parylene-C that is 20 times thinner than a human hair. Rui Jing co-founded the company in 2017 as a junior at Penn's Wharton School, won the $100,000 President's Innovation Prize in 2018, secured FDA Investigational Device Exemption approval in October 2025 for the US SAPPHIRE trial, and closed a $10.7M Series A in February 2026 to advance pivotal clinical development.
Shawn O'Neil is the CEO of ViaLase, a clinical-stage medtech company building FLIGHT, an incision-free femtosecond laser procedure for glaucoma. He spent more than two decades at Alcon rising to head of sales and marketing for surgical glaucoma, then ran commercial at Sight Sciences before joining ViaLase as Chief Commercial Officer and stepping up to CEO in July 2025. His career has been a running tour of the products that reshaped eye surgery: EX-PRESS, LenSx, CyPass, OMNI, TearCare, and now a laser that treats glaucoma without ever touching the eye with a blade.
Andrew Huberman is a tenured professor of neurobiology and ophthalmology at Stanford University School of Medicine and the host of the Huberman Lab podcast - regularly ranked the #1 health and science podcast in the world with over 400 episodes. His Stanford lab investigates visual system repair, neural plasticity, and stress resilience, publishing in Nature, Science, and Cell. A former skateboarder who once wrote for Thrasher magazine and lobbied the Palo Alto city council to build a skate park at age 13, Huberman translates complex neuroscience into actionable protocols for millions of listeners globally.
Robert Chang is the President and CEO of Myra Vision, a Campbell, California medtech company developing the Calibreye Titratable Glaucoma Therapy (TGT) Surgical System - an adjustable aqueous shunt designed to give glaucoma surgeons real-time, non-invasive control over intraocular pressure. With over 30 years of medical device executive experience spanning co-founding Ample Medical, leading MVRx, and serving as CTO at Sadra Medical (acquired by Boston Scientific), Chang brings a rare combination of hands-on engineering depth and serial CEO-level leadership to one of ophthalmology's most intractable surgical challenges. Myra Vision has raised $50M+ across seed, Series A, and a $25M Series B in 2023, and in early 2026 enrolled its first patient in the FDA-approved ADAPT pivotal study.